There are now novel treatment approaches under investigation that focus on inhibitors of the NLRP3 inflammasome pathway due to its crucial role in NOMID pathogenesis; these include MCC950, β-hydroxybutyrate, tranilast, autophagy, and microRNAs (38–40). Here, NLRP3 is linked to CINCA syndrome.